Floatz logo

Busulphan

IDH2 Gene Mutation

University of UtahPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the IDH2 Gene Mutation cohort.

Asset / SponsorPhaseRating
Enasidenib
University Health Network, Toronto
Phase 2BB
Cyclophosphamide
University of Utah
Phase 2CCC
Romidepsin
University of Utah
Phase 2CCC
Azacitidine
M.D. Anderson Cancer Center
Phase 2CCC
Fludarabine
University of Utah
Phase 2CCC
Venetoclax
University Health Network, Toronto
Phase 1/2CCC
Pamiparib
University of California, San Francisco
Phase 1CC

Same molecule, other indications

Busulphan is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BBB
Indicative ·
76 / 100
View asset →
graft versus host diseaseDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →